Large market reach Signant Health serves 90+ countries and has supported over 6,000 studies, indicating a broad global footprint and capabilities to manage multinational trials that require scalable eClinical solutions.

Acquisition momentum Recent strategic activity includes the planned acquisition of Ametris, signaling expansion of technology capabilities and potential cross-sell opportunities with an expanded product and services portfolio.

Clinical leadership Signant has strengthened its clinical leadership with multiple Clinical Vice Presidents and a focus on specialized therapeutic areas such as metabolic disease, diabetes, obesity, and epilepsy, presenting opportunities to tailor high-value endpoints and PRO measures.

Regulatory impact With a track record contributing to a significant share of recent FDA and EMA drug approvals, there is a strong value proposition for sponsors seeking robust evidence generation, high data quality, and regulatory-aligned endpoints.

Industry engagement Active participation in key industry events and partnerships with organizations like The Epilepsy Study Consortium demonstrates ongoing collaboration and opportunities to co-develop innovative measurement solutions and eClinical offerings.